Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126012721 | 12601272 | 1 | I | 201605 | 20160721 | 20160728 | 20160728 | EXP | FR-AFSSAPS-AN20160737 | FR-009507513-1607FRA009607 | MERCK | 84.53 | YR | M | Y | 0.00000 | 20160728 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126012721 | 12601272 | 1 | PS | NASONEX | MOMETASONE FUROATE | 1 | Nasal | 50 MICROGRAM/DOSE | Y | N | 20762 | 50 | UG | NASAL SPRAY, SUSPENSION | |||||
| 126012721 | 12601272 | 2 | SS | PANTOPRAZOLE | PANTOPRAZOLE SODIUM | 1 | Oral | 40MG, QD | Y | N | 0 | 40 | MG | QD | |||||
| 126012721 | 12601272 | 3 | C | VINDESINE SULFATE | VINDESINE SULFATE | 1 | Intravenous (not otherwise specified) | 5.3 MG, IN ONE CYCLE-239 DAYS | Y | N | 0 | 5.3 | MG | ||||||
| 126012721 | 12601272 | 4 | C | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | 1300 MG, IN ONE CYCLE-239 DAYS | Y | N | 0 | ||||||||
| 126012721 | 12601272 | 5 | C | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 44 MG, IN ONE CYCLE | Y | N | 0 | 44 | MG | ||||||
| 126012721 | 12601272 | 6 | C | RITUXIMAB | RITUXIMAB | 1 | Subcutaneous | 1400 MG, IN ONE CYCLE | Y | N | 0 | ||||||||
| 126012721 | 12601272 | 7 | C | CORTANCYL | PREDNISONE | 1 | Oral | 2 DF PER CYCLE | Y | N | 0 | 2 | DF | ||||||
| 126012721 | 12601272 | 8 | C | SOLUPRED | PREDNISOLONE | 1 | Oral | 90 MG, QD FROM DAY 1 TO DAY 5 | Y | N | 0 | 90 | MG | ||||||
| 126012721 | 12601272 | 9 | C | PERINDOPRIL | PERINDOPRIL | 1 | Oral | 5 MG QD | 0 | 5 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126012721 | 12601272 | 1 | Product used for unknown indication |
| 126012721 | 12601272 | 2 | Product used for unknown indication |
| 126012721 | 12601272 | 3 | Non-Hodgkin's lymphoma |
| 126012721 | 12601272 | 4 | Non-Hodgkin's lymphoma |
| 126012721 | 12601272 | 5 | Non-Hodgkin's lymphoma |
| 126012721 | 12601272 | 6 | Non-Hodgkin's lymphoma |
| 126012721 | 12601272 | 7 | Non-Hodgkin's lymphoma |
| 126012721 | 12601272 | 8 | Non-Hodgkin's lymphoma |
| 126012721 | 12601272 | 9 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126012721 | 12601272 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126012721 | 12601272 | Hyponatraemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126012721 | 12601272 | 1 | 2013 | 20160523 | 0 | |
| 126012721 | 12601272 | 2 | 201508 | 0 | ||
| 126012721 | 12601272 | 3 | 20150824 | 20160418 | 0 | |
| 126012721 | 12601272 | 4 | 20150824 | 20160418 | 0 | |
| 126012721 | 12601272 | 5 | 20151109 | 20160418 | 0 | |
| 126012721 | 12601272 | 6 | 20150908 | 20160418 | 0 | |
| 126012721 | 12601272 | 7 | 20151109 | 20160418 | 0 | |
| 126012721 | 12601272 | 8 | 20150824 | 20160418 | 0 | |
| 126012721 | 12601272 | 9 | 2013 | 0 |